Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | HBB | P68871 | 2/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | STAT6 | P42226 | 1/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789515 | 0.87 | TOP1 (0.76) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL1006809 | 0.87 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27502805 | 0.87 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6782602 | 0.86 | TOP1 (0.58) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6788914 | 0.85 | TOP1 (0.60) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6792999 | 0.84 | TOP1 (0.61) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6786007 | 0.82 | TOP1 (0.80) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL5859831 | 0.80 | TOP1 (0.75) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL8322065 | 0.80 | TOP1 (0.87) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6788663 | 0.79 | TOP1 (0.72) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699876-B2 | FOR CANCER THERAPY | LES LABORATOIRES SERVIER (FR) | 2004-03-02 | — | — | US | disclosed |
| US-20030105109-A1 | For cancer therapy | LES LABORATOIRES SERVIER (FR) | 2003-06-05 | — | — | US | disclosed |
| US-6509345-B2 | For therapy of cancerous diseases | LES LABORATOIRES SERVIER (FR) | 2003-01-21 | — | — | US | disclosed |
| EP-1101765-B1 | Camptothecin analogues, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-08-14 | — | — | EP | disclosed |
| US-20020077325-A1 | New camptothecin analogue compounds | LAVIELLE GILBERT (FR) | 2002-06-20 | — | — | US | disclosed |
| EP-1101765-A2 | Camptothecin analogues, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105109-A1 | For cancer therapy | OXER1, OXGR1, CBR1 | TOP1 360/4885MEN1 4478/4885KMT2A 2823/4885 |
| US-20020077325-A1 | New camptothecin analogue compounds | OXER1, CBR3, CBR1 | TOP1 18/4885MEN1 4035/4885KMT2A 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.